Patient participating in MINDSET 2 clinical study for Alzheimer's disease treatment

MINDSET 2 Study: Testing a New Pill Treatment for Alzheimer's disease

MINDSET 2 is a phase 3 clinical trial conducted by Bristol-Myers for people with mild to moderate Alzheimer's disease. The study tests whether a new pill treatment (KarXT + KarX-EC) is safe and can help with thinking and memory problems. This is an experimental treatment not yet approved by the FDA.

Participate in the study

Eligibility Criteria

60 to 85 years old
Mild to moderate Alzheimer's disease
Designated caregiver required
Oral medication

Study goal and designEvaluating KarXT + KarX-EC for cognitive impairment

This Phase 3 clinical trial conducted by Bristol-Myers is testing whether the new pill treatment (KarXT + KarX-EC) is safe and can improve memory, thinking, and daily functioning in people with mild to moderate Alzheimer's disease.

Participants will be randomly assigned to receive either the experimental treatment or a placebo, so researchers can compare the effects. These drugs are still investigational and have not yet been approved by the FDA.

More info
Neurologist evaluating cognitive impairment treatment with KarXT and KarX-EC
Family support and comprehensive medical care during MINDSET 2 clinical trial

Study-related care and supportComprehensive medical evaluations and monitoring

While contributing to research, participants receive:

  • The possibility to receive the investigational study drug (KarXT + KarX-EC)
  • Regular cognitive assessments and medical evaluations
  • Study visits with qualified medical professionals
  • Brain magnetic resonance imaging (MRI) assessments

All medical and travel costs related to the study are covered. Participants must have a designated caregiver who maintains adequate contact (around 10 hours per week or more) and is willing to attend all study visits.

Volunteer journeyA structured study process

1 - Express your interest: Answer a questionnaire to check preliminary criteria and confirm eligibility.

2 - Meet the study team: Take part in comprehensive cognitive assessments and medical evaluations including MMSE testing.

3 - Begin treatment (or placebo): Receive investigational treatment (KarXT + KarX-EC) or placebo orally at specified doses on specified days. Participation duration is 24 weeks.

4 - Continue the study: Be monitored during regular follow-up visits with cognitive assessments and medical check-ups to evaluate treatment effects.

Neuropsychological evaluation during MINDSET 2 clinical trial volunteer journey

Have questions?

Feel free to contact us at the address below:

research@docmemo.com